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ABSTRACT
Type 2 diabetes mellitus (T2DM) is a progressive 
multisystemic disease that increases significantly 
cardiovascular morbidity and mortality. It is 
associated with obesity, insulin resistance, 
beta-cell dysfunction, and hyperglucagonemia, 
the combination of which typically leads 
to hyperglycemia. Incretin-based treatment 
modalities, and in particular glucagon-like 
peptide 1 (GLP-1) receptor agonists, are able 
to successfully counteract several of the 
underlying pathophysiological abnormalities of 
T2DM. The pancreatic effects of GLP-1 receptor 
agonists include glucose-lowering effects by 
stimulating insulin secretion and inhibiting 
glucagon release in a strictly glucose-dependent 
manner, increased beta-cell proliferation, and 
decreased beta-cell apoptosis. GLP-1 receptors 
are widely expressed throughout human body; 
thus, GLP-1-based therapies exert pleiotropic 
and multisystemic effects that extend far 
beyond pancreatic islets. A large body of 
experimental and clinical data have suggested 
a considerable protective role of GLP-1 analogs 
in the cardiovascular system (decreased blood 
pressure, improved endothelial and myocardial 
function, functional recovery of failing 
and ischemic heart, arterial vasodilatation), 
kidneys (increased diuresis and natriuresis), 
gastrointestinal tract (delayed gastric 
emptying, reduced gastric acid secretion), and 
central nervous system (appetite suppression, 
neuroprotective properties). The pharmacologic 
use of GLP-1 receptor agonists has been shown 
to reduce bodyweight and systolic blood 
pressure, and significantly improve glycemic 
control and lipid profile. Interestingly, weight 
reduction induced by GLP-1 analogs reflects 
mainly loss of abdominal visceral fat. The 
critical issue of whether the emerging positive 
cardiometabolic effects of GLP-1 analogs can 
be translated into better clinical outcomes for 
diabetic patients in terms of long-term hard 
endpoints, such as cardiovascular morbidity 
and mortality, remains to be elucidated with 
prospective, large-scale clinical trials.102 Diabetes Ther (2011)  2(2):101-121.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is globally one 
of the most challenging public health problems 
of the twenty-first century. It is a complex, 
progressive multisystemic disease with serious, 
potentially life-threatening microvascular and 
macrovascular complications. According to 
current estimations, the overall prevalence 
of T2DM is expected to rise to 380 million by 
year 2025.1 If these ominous predictions for 
future diabetes prevalence finally come true, 
it is estimated that direct diabetes-associated 
healthcare costs will represent 7% to 13% of the 
global healthcare budget.2
Defective insulin secretion and impaired 
hepatic and peripheral insulin action constitute 
the major pathophysiological mechanisms 
underlying T2DM pathogenesis. However, it is 
the progressively deteriorating beta-cell function 
(pancreatic beta-cell failure), which ultimately 
leads to chronic hyperglycemia, and is critical 
to disease development and prognosis. Although 
beta-cell dysfunction is considered to be an 
acquired mechanism of diabetes progression, 
recent evidence suggests that the primary 
genetic defect contributing to T2DM is impaired 
beta-cell function, with genetically predisposed 
individuals possessing a reduced capacity to 
overcome peripheral insulin resistance.3 The 
beta-cell plays, therefore, a central pathogenetic 
role for T2DM, and treatment modalities 
exerting beneficial effects on beta-cell functional 
parameters are increasingly recognized as 
promising tools for T2DM management.
Successful treatment of T2DM is often 
complicated by the inevitably progressive 
nature of the disease and the need to balance 
target blood glucose levels against an increased 
risk of treatment-related adverse effects such 
as hypoglycemia and weight gain. Adherence 
of patients to treatment is often compromised 
by the fear of hypoglycemia and weight gain, 
as well as by complex therapeutic regimens. 
The convenience and flexibility of antidiabetic 
regimens is known to positively impact 
treatment compliance.4 For example, elderly 
patients, particularly those with some degree of 
cognitive dysfunction, are likely to experience 
difficulties in adhering to high-complexity 
regimens, involving frequent dosing, regular 
blood glucose monitoring, or meal planning.4
It becomes increasingly clear, that simplified 
antidiabetic regimens that reduce dosing 
frequency, minimize requirements for blood 
glucose testing and are not meal-dependent, 
can prove to be particularly beneficial for 
specific subgroups of difficult-to-treat patients.4
Of course, it is important to highlight that 
the safest and most effective way to manage 
T2DM without fear of drug-related side-effects 
is through comprehensive lifestyle modification 
and nonpharmacological weight loss, which is 
the recommended initial treatment approach for 
all T2DM patients. Although it is acknowledged 
that lifestyle interventions are difficult to 
ensure long-term compliance, it is important 
to emphasize that no pharmacological therapy 
is likely to be ultimately successful, without 
concomitant synergistic lifestyle changes. The 
role of lifestyle modification in optimizing 
outcomes of antidiabetic drug therapy is, 
therefore, of paramount importance, and should 
never be neglected or underestimated.
An optimal antidiabetic drug therapy should 
provide adequate glycemic control with minimal 
or no risk of hypoglycemia, augment the residual 
beta-cell functional capacity and in addition, 
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hyperglycemia, such as obesity, hypertension, 
and dyslipidemia, so that a wide range of clinically 
significant cardiometabolic benefits may result. 
Despite the existing large armamentarium of 
oral antidiabetic agents, current therapy provides 
only a suboptimal solution, as the prevalence of 
adequate glycemic control remains unacceptably 
low (<40%).5 Many of the existing antidiabetic 
treatment options do not provide sustained 
glycemic control, can induce weight gain, and 
have negligible effect on the underlying beta-
cell dysfunction.5-7 A relatively novel class of 
antidiabetic agents, incretin hormone glucagon-
like peptide 1 (GLP-1) analogs or GLP-1 receptor 
agonists, represent a whole new therapeutic 
direction for T2DM management, and offer an 
attractive alternative approach to many aspects 
of diabetes pathophysiology.
The present review provides a concise 
overview of multiple GLP-1 pancreatic and 
extrapancreatic physiological effects, and 
summarizes most recent preclinical and clinical 
data substantiating the role of GLP-1 analogs in 
current T2DM therapeutic algorithms.
THE INCRETIN EFFECT AND 
GLUCAGON-LIKE PEPTIDE 1 
THERAPY
GLP-1 is a 30-amino-acid polypeptide derived 
from the proglucagon gene that is rapidly secreted 
into the bloodstream from enteroendocrine 
L-cells in the distal small intestine and the colon 
in response to food ingestion.8 Within the L-cells 
of the small intestine, proglucagon peptide is 
processed by enzyme prohormone convertase 
1/3 to GLP-1, GLP-2 (a key regulator of small 
intestinal growth), and glicentin.
GLP-1 is characterized as a pluripotent 
natural incretin hormone, which exerts multiple 
physiological actions throughout the human 
body. The name “incretin” is derived from the 
Latin word increscere (meaning “to increase”) 
and refers to the strong insulinotropic effect on 
pancreatic beta-cells of the incretin hormones 
GLP-1 and glucose-dependent insulinotropic 
polypeptide (GIP).
The incretin effect has been typically 
described by the observation that when 
glucose is administered orally, it results in 
a much more profound increase in plasma 
insulin concentrations compared with the 
insulin increase after intravenous glucose 
administration, despite equivalent blood glucose 
profiles.9 Incretin hormones (GLP-1 and GIP) 
account for 50% to 70% of postprandial insulin 
secretion from pancreatic beta-cells.9 The direct 
intraluminal contact between ingested nutrients 
and GLP-1 secreting L-cells is the major 
stimulus for GLP-1 secretion, while additional 
neuroendocrine signals (acetylcholine, gastrin-
releasing peptide, and GIP) are also important 
contributing factors.9 GLP-1 postprandial 
secretion is actually biphasic: an early phase 
of 15-30 minutes, mediated by neural and 
endocrine factors, is subsequently followed 
by a more sustained phase of 30-60 minutes, 
stimulated by the contact of nutrients with the 
intestinal mucosa.10 Shortly after its secretion, 
GLP-1 is rapidly degraded by the ubiquitous 
enzyme dipeptidyl peptidase 4 (DPP-4), which 
cleaves off the two N-terminal residues of GLP-
1, inactivating the hormone.11 DPP-4 is found in 
numerous human tissues. The soluble form of 
DPP-4, which is found in plasma, is responsible 
for the short half-life of the plasma circulating 
GLP-1 (approximately 1-1.5 minutes). 
Native GLP-1 has, therefore, limited therapeutic 
utility, as a continuous infusion would be 
required to achieve sustained in-vivo efficacy. 
To overcome the major therapeutic limitation 
of poor native GLP-1 viability due to its short 
half-life, longer-acting GLP-1 analogs have been 
clinically developed, providing all the positive 104 Diabetes Ther (2011)  2(2):101-121.
effects of GLP-1 with a protracted mechanism 
of action.
GLP-1 multiorgan and multisystemic 
activity is largely mediated by the 
GLP-1 receptor (GLP-1R), which is a member 
of family B1 of the seven-transmembrane 
G protein-coupled receptors.12 This receptor 
displays a wide tissue distribution and 
is localized in many organs, including 
the pancreatic islets, kidneys, heart, 
lungs, gastrointestinal tract (stomach and 
duodenum), pituitary, endothelium and parts 
of the peripheral and central nervous system.9
When GLP-1R binds and interacts with either 
endogenous GLP-1 ligand or exogenously 
administered GLP-1R agonists (GLP-1 analogs), 
pancreatic beta-cells are stimulated to secrete 
insulin in a glucose-dependent manner via 
activation of enzyme adenylcyclase, which 
results in increased intracellular levels of 
cyclic adenosine monophosphate, namely the 
crucial intracellular mediator of GLP-1 effects.9
In addition to potentiating insulin secretion, 
GLP-1 can also promote insulin biosynthesis 
from the pro-insulin gene, while it can 
significantly affect pancreatic alpha-cells, 
exerting a glucose-dependent suppressive effect 
on glucagon secretion.13,14 Given that GLP-1 
stimulates insulin secretion and suppresses 
glucagon secretion only when blood glucose 
levels are truly elevated, it is important to 
emphasize that GLP-1-based therapy does 
not impair the counterregulatory response of 
glucagon to hypoglycemia, thus protecting 
against hypoglycemic episodes. Of note are 
intriguing experimental observations from 
recent animal and human in-vitro studies that 
GLP-1 is able to suppress cytokine-mediated 
beta-cell apoptosis, stimulate beta-cell 
neogenesis and proliferation, and substantially 
increase functional beta-cell mass.15
The above indicate that GLP-1 is 
able to successfully counteract multiple 
pathophysiological traits underlying T2DM, 
and not just defective insulin secretion. Table 1 
describes in a schematic way the mechanisms, 
by which natural incretin GLP-1 and thus GLP-
1-based therapy address the major abnormalities 
observed in T2DM patients.16
In healthy individuals, levels of GLP-1 are 
in the range of 5-10 pmol/L in the fasting state 
and 20-40 pmol/L postprandially.8 Conflicting 
findings exist concerning GLP-1 concentrations 
in patients with T2DM. One study demonstrated 
Table 1. Characteristic abnormalities in T2DM and associated actions of GLP-1 in response to every abnormality (adapted 
from reference 16).
T2DM abnormality GLP-1 action
Defective insulin secretion Glucose-dependent stimulation of insulin secretion
Blunted insulin response to meals Improved insulin response tomeals (first-phase response)
Loss or reduction of incretin effect Restoration of incretin activity, enhanced incretin effect
Hyperglucagonemia Suppression of glucagon secretion at high glucose levels
Reduced beta-cell insulin content Increased insulin biosynthesis
Reduced beta-cell mass Increased beta-cell mass, differentiation of precursor cells into beta-cells
Abnormally high rate of beta-cell apoptosis Inhibition of glucotoxicity-induced beta-cell apoptosis
Often overweight or obese Suppression of appetite and decelerated gastric emptying, induction of 
satiety, weight loss
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significantly reduced GLP-1 levels in a population 
of T2DM patients compared with appropriately 
matched healthy controls, although there 
was no difference between groups for the first 
60 minutes following intake of a test meal.17 It 
is, however, well established that the beta-cell 
insulin secretory response to physiological levels 
of GLP-1 is severely impaired in T2DM.18 This 
defective insulin response (impaired incretin 
effect) can be restored to normal with sustained 
pharmacological levels of native GLP-1 
(126 pmol/L).19
INCRETIN BIOLOGY BEYOND THE 
PANCREAS
As a result of the broad tissue distribution of 
GLP-1R expression, GLP-1 exerts a pleiotropic 
range of favorable extrapancreatic effects, 
extending far beyond the Islets of Langerhans. 
These mainly affect gastrointestinal tract 
motility, centrally mediated appetite regulation, 
and cardiovascular function.
Figure 1 illustrates the manifold localization 
of GLP-1 receptors throughout the human body, 
Figure 1. Major sites of GLP-1 action in the human body, illustrating its pleiotropic physiological effects. GLP-1=glucagon-
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emphasizing the multifaceted physiology of this 
gut-derived hormone, which can also explain 
the pleiotropic effects of incretin-based therapy.
Gastrointestinal Effects of Glucagon-like 
Peptide 1
GLP-1 has been identified as a potent inhibitor 
of several upper gastrointestinal functions such 
as gastric acid secretion, pancreatic exocrine 
secretion, gastric emptying, and gastrointestinal 
motility, thereby decelerating the entry of 
nutrients into circulation and preventing 
exaggerated blood glucose excursions. These 
inhibitory actions of GLP-1 are thought to 
be part of the so-called “ileal brake effect”— 
namely the endocrine retrograde inhibition of 
upper gastrointestinal secretion and motility 
elicited by the presence of nutrients into 
the distal ileum.20 More specifically, GLP-1 
has been found to significantly delay gastric 
emptying rate following meal consumption. 
In one study in 14 healthy volunteers, 
6 hours after a solid 250 kcal mixed meal 
consumption, most of the food had gone 
from the stomach during placebo infusion, 
whereas approximately 50% still remained 
in the stomach, 360 minutes after the start 
of the GLP-1 infusion.21 The deceleration of 
gastric content evacuation, observed both in 
rodents and humans, is thought to involve 
the gut-brain axis and to be mediated by GLP-
1Rs on afferent sensory vagal nerves. However, 
after vagal denervation, GLP-1 was still able 
to inhibit—to some extent—gastric motility 
in pigs, raising the possibility that GLP-1 
regulates gastric emptying not only through 
afferent neural pathways, but also via direct 
gut-specific mechanisms.22 Apart from slowing 
gastric emptying, GLP-1 infusion has also 
been shown to significantly reduce gastric acid 
secretion via neurally mediated mechanisms.23
Central Nervous System Effects of Glucagon-
like Peptide 1
GLP-1 is a proven key regulator of short-term 
and long-term energy homeostasis, considering 
that GLP-1Rs are abundantly expressed in 
brainstem and hypothalamic areas that regulate 
appetite and food intake. In an interesting study 
in T2DM patients, GLP-1 infusion increased 
significantly subjective feelings of fullness and 
postprandial satiety, while it decreased hunger 
sensation and prospective food intake.24 The 
observed anorexigenic effect induced by 
GLP-1 infusion in fasted individuals suggests 
that GLP-1 can affect satiety independently 
of delayed gastric emptying. In this context, 
it is important to note that GLP-1 is not only 
peripherally produced by L-cells of the small 
intestine, but is also centrally synthesized 
by a small distinct population of neurons 
within nucleus of solitary tract in the caudal 
brainstem.25 Current evidence suggests that both 
central and peripheral GLP-1 play a synergistic 
role in regulating food intake. According to 
the current model, food ingestion promotes 
GLP-1 release from the intestine. Along with 
gastric distension, this leads to activation of 
vagal afferent nerves, which in turn activate 
GLP-1-producing neurons projecting to the 
paraventricular nucleus of hypothalamus, 
where GLP-1R activation promotes anorexia 
and satiety.25 Further investigation is required 
to determine the relative contribution of 
peripheral and central GLP-1 to energy and 
glucose homeostasis, and delineate the specific 
sites of action for each function.
Another clinically relevant central effect of 
incretins consists in cognitive improvement 
and neuroprotection conferred by GLP-1 in 
rodents, rendering incretin-based therapy an 
attractive theoretical treatment modality for 
Alzheimer’s disease.26Diabetes Ther (2011)  2(2):101-121. 107
Cardiovascular Effects of Glucagon-like 
Peptide 1
Cardiovascular risk factors can be definitely 
affected by the weight-reducing and glucose-
lowering effects associated with GLP-1-
based therapy. However, emerging studies 
suggest that GLP-1 and GLP-1 analogs 
exert additional beneficial effects on the 
cardiovascular system independently of their 
glucose-lowering potential.27
In experimental models, GLP-1 has been 
shown to exert a wide range of cardiovascular 
effects, such as modulation of heart rate, 
blood pressure, myocardial contractility, 
vascular tone, and protection against ischemia-
reperfusion injury.27 Structural and functional 
cardiac abnormalities have been demonstrated 
in mice lacking the GLP-1R, suggesting that 
endogenous GLP-1 plays an important role in 
cardiovascular system integrity.28 Nikolaidis et 
al. showed that GLP-1 increased glucose uptake 
and left ventricular performance in dogs with 
pacing-induced dilated cardiomyopathy.29
Furthermore, a recent study showed that 
GLP-1 analog exenatide reduced infarct size 
and enhanced cardiac function in a porcine 
model of ischemia-reperfusion injury,30 while 
another recent study showed that 3 months 
of continuous infusion of GLP-1 resulted 
in increased survival and preserved cardiac 
function in a rat model of diabetes and 
hypertension.31 The GLP-1 analog liraglutide 
has also been shown to activate cytoprotective 
pathways and improve outcomes after 
experimental myocardial infarction in mice.32
In canine models of cardiac injury and heart 
failure, GLP-1 and its metabolically inactive 
metabolite GLP-1(9-36) improved myocardial 
function and cardiac output, while it decreased 
left ventricular end-diastolic pressure, heart 
rate, and systemic vascular resistance.29
In the human cardiovascular system, 
GLP-1R is expressed in cardiomyocytes, 
coronary endothelial cells, and vascular 
smooth muscle cells.27 Nikolaidis et al. 
reported that GLP-1 administration, when 
added to standard therapy, improved regional 
and global left ventricular function in patients 
with acute myocardial infarction after primary 
angioplasty.33 Furthermore, in a clinical 
setting, GLP-1 augmented left ventricular 
ejection fraction and functional status in 
patients with congestive heart failure.34
The same research group reported that 
perioperative use of GLP-1 improved glycemic 
control without need for high-dose insulin 
or inotropic drugs in patients undergoing 
coronary artery bypass grafting.35 Interestingly, 
beneficial effects of GLP-1 on cardiovascular 
risk factors have been demonstrated in both 
healthy and diabetic subjects. Three years 
of exenatide treatment in T2DM patients 
resulted in significant reductions of systolic 
and diastolic blood pressure, without affecting 
the heart rate.36 Nikolaidis et al. reported that 
72 hours of continuous GLP-1 infusion after 
coronary revascularization increased the 
ejection fraction and the regional and global 
wall motion indices in both diabetic and 
nondiabetic patients with acute myocardial 
infarction.33 Furthermore, intravenous 
GLP-1 infusion was shown to improve the 
blood pressure and cardiac function in the 
postoperative state after coronary artery 
bypass grafting in patients with T2DM.37
Clinical studies examining T2DM patients 
with coronary artery disease have also shown 
that GLP-1 infusion was able to improve the 
endothelial function, which is a surrogate 
marker of the overall atherosclerotic burden.38
It should be particularly emphasized that 
GLP-1-based therapy appears to improve a wide 
range of cardiovascular risk factors, including 108 Diabetes Ther (2011)  2(2):101-121.
hypertension, dyslipidemia and subclinical 
low-grade inflammation.36 However, large-scale 
and well-designed studies are needed in order 
to investigate the impact of cardiovascular risk 
reduction induced by GLP-1-based treatment 
on hard cardiovascular endpoints, including 
morbidity and mortality.
Whether GLP-1’s favorable effects on the 
cardiovascular system are mediated exclusively 
through GLP-1R or another as yet unidentified 
receptor has not been fully elucidated. However, 
some studies suggest that the presumably 
inactive metabolite GLP-1(9–36) may improve 
functional recovery in ischemic heart via 
mechanisms unrelated to GLP-1R.28
Other Extrapancreatic Effects of Glucagon-
like Peptide 1
GLP-1 may exert an anabolic effect on 
the liver, resulting in increased glycogen 
synthesis from circulating glucose, while 
it also suppresses hepatic glucose output 
(gluconeogenesis) via inhibited pancreatic 
glucagon secretion.10 Moreover, recent data 
suggest that GLP-1-induced inhibition of the 
tubular Na+/H+ exchanger isoform 3 increases 
urinary sodium excretion, exerting thus 
natriuretic and diuretic effects, which could 
partly contribute to the observed blood 
pressure reduction achieved with human 
GLP-1 analogs.39 In addition, GLP-1 has shown 
to decrease glomerular hyperfiltration, and 
it has been speculated that this effect could 
possibly contribute to clinically significant 
renoprotection.40 Finally, GLP-1R mRNA has 
been found in rat type 2 pneumocytes, and 
both GLP-1 and exenatide have shown to 
stimulate secretion of phosphatidylcholine, 
which is a major component of lung 
surfactant.41 The clinical implications of the 
latter observation remain unresolved.
GLUCAGON-LIKE PEPTIDE 1 
ANALOGS VERSUS ORAL 
DIPEPTIDYL PEPTIDASE 4 
INHIBITORS
DPP-4 inhibitors, such as sitagliptin, vildagliptin, 
and saxagliptin, are an alternative treatment 
strategy to using GLP-1 analogs. These oral 
agents prevent GLP-1 degradation, thus 
increasing the plasma levels of endogenous 
GLP-1 to physiological levels (in the range 
10-25 pmol/L). However, data suggest that the 
relatively modest physiological levels of GLP-1 
achieved with DPP-4 inhibitors may be the 
reason for the neutral bodyweight effect and less 
Table 2. Differential efficacy, tolerability, and administration characteristics between DPP-4 inhibitors and GLP-1R 
agonists.
DPP-4 inhibitors GLP-1R agonists
Both GLP-1 and GIP enhanced Pure GLP-1 effect
Increased levels of GLP-1 in Pharmacological levels of GLP-1 physiological range
Limited by endogenous secretion Not limited by endogenous secretion
Moderate efficacy Enhanced efficacy
Well tolerated Nausea, gastrointestinal side-effects
No weight change Weight loss
Oral route of administration Subcutaneous injection
DPP-4=dipeptidyl peptidase-4; GIP=glucose-dependent insulinotropic polypeptide; GLP-1=glucagon-like peptide 1; GLP-
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pronounced blood glucose reduction observed 
with this category, when compared with GLP-1R 
agonists.42 This is in contrast with the significant 
weight loss and HbA1c reduction observed 
with GLP-1 analogs, which provide high 
pharmacological steady-state levels of GLP-1R 
agonist sufficient to restore the impaired beta-
cell insulin secretory response of T2DM patients 
to levels similar to those of healthy adults.
The differential characteristics of these 
two types of incretin-based treatments are 
schematically presented in Table 2.
CLINICAL EFFICACY OF DAILY 
(SHORT-ACTING) GLUCAGON-LIKE 
PEPTIDE 1 ANALOGS
Exenatide: a Twice-Daily Glucagon-like 
Peptide 1 Mimetic
Exenatide is a subcutaneously injected incretin 
mimetic, which needs to be preprandially 
administered twice per day. It is indicated as 
adjunctive therapy for patients with T2DM who 
are already receiving antidiabetic therapy with 
metformin, a sulfonylurea, or both, but continue 
to have suboptimal glycemic control.
Exenatide was originally isolated from 
the saliva of the venomous lizard Heloderma
suspectum (Gila monster) in a search for 
biologically active peptides.43 It shares only 53% 
amino acid sequence homology with native 
GLP-1, but exenatide and naturally occurring 
GLP-1 are equipotent with regard to binding and 
activation of GLP-1Rs on pancreatic beta-cells.44
After subcutaneous administration, exenatide is 
rapidly absorbed, reaching peak concentrations 
in approximately 2 hours.45 As it is primarily 
cleared through the kidneys by glomerular 
filtration, the plasma half-life of subcutaneously 
administered exenatide is 2-3 hours, which is 
prohibitive for once-daily dosing.46
In three phase 3 placebo-controlled clinical 
trials that enrolled a total of 1446 patients 
who received 5 or 10 μg exenatide twice 
daily, or placebo for 30 weeks, the addition of 
exenatide to the pre-existing treatment with 
metformin, sulfonylurea, or both, was associated 
with significant reductions of HbA1c.47 Most 
exenatide-treated patients achieved a target 
HbA1c of ≤7%, a significant decrease in fasting 
plasma glucose concentrations, and a dose-
dependent progressive weight loss.47 Nausea was 
the most commonly reported adverse event in 
the combined exenatide groups, reaching the 
level of 43.5%. Based on the limited homology 
of exenatide with native human GLP-1, the 
incidence of anti-exenatide antibodies was as 
high as 43% at 30 weeks in the exenatide phase 3 
development program.48 According to some 
recent evidence, such high immunogenicity 
could attenuate, to some extent, the clinical 
efficacy of exenatide.49 Subjects completing 
3 consecutive years of exenatide exposure in 
these phase 3 trials were all enrolled into an 
open-label clinical trial, aimed at evaluating 
the effects of prolonged exenatide therapy on 
glycemic control, bodyweight, cardiometabolic 
risk markers, and safety. Interestingly, HbA1c
and bodyweight reductions were significantly 
sustained at 3 years, while it is noteworthy that 
exenatide-treated patients exhibited minor but 
significant reductions in total cholesterol, low-
density lipoprotein cholesterol, triglycerides, 
and hepatic aminotransferases.36 The substantial 
improvement in the lipid profile and hepatic 
biochemistry of patients treated with exenatide 
was coupled with a progressive weight loss of 
approximately 5 kg from baseline to the end of 
the 3-year study period.36
The concomitant use of exenatide and 
insulin is currently not US Food and Drug 
Administration (FDA) approved, due to the lack 
of solid clinical evidence. However, a combined 110 Diabetes Ther (2011)  2(2):101-121.
regimen of insulin and exenatide might be 
advantageous, especially for mitigating insulin-
related weight gain in obese T2DM patients.50
Several small prospective and retrospective 
studies evaluating the potential advantages 
of combination therapy reported significant 
reductions in HbA1c, bodyweight, and total daily 
insulin dose requirements.50
In an additional open-label noninferiority 
trial, treatment with exenatide 10 μg twice 
daily and appropriately titrated insulin glargine 
for 16 weeks were interestingly associated with 
similar reductions in HbA1c, when combined 
with a single oral antidiabetic agent.51 Exenatide 
therapy proved to be more beneficial than 
insulin glargine in terms of reducing bodyweight 
and postprandial glucose excursions, whereas 
insulin glargine was more effective in improving 
fasting hyperglycemia. Based on the positive 
metabolic effects of exenatide use in conjunction 
with oral antidiabetic agents (metformin, 
sulfonylurea, or thiazolidinediones), Moretto et 
al. aimed to evaluate the efficacy and tolerability 
of exenatide as monotherapy in antidiabetic 
drug-naive T2DM patients, and suggested that 
exenatide monotherapy might be a viable 
treatment option for drug-naive T2DM patients 
who are inadequately controlled with diet or 
exercise alone.52
Liraglutide: a Once-Daily Human Glucagon-
like Peptide 1 Analog
The structure of liraglutide is based on native 
human GLP-1. However, there are two important 
modifications to the native molecule that make 
liraglutide less susceptible to DPP-4 degradation, 
giving it a half-life of approximately 13 hours: the 
attachment of a C16 fatty acid side chain linked 
via a glutamoyl spacer to lysine at position 26, 
and replacement of lysine with arginine at 
position 34, providing only one binding site for 
the fatty acid side chain.53 As there is only one 
amino acid substitution, the resultant molecule 
of liraglutide shares 97% amino acid sequence 
identity (homology) with native human GLP-1. 
Following subcutaneous injection, the fatty acid 
side chain allows liraglutide to self-associate into 
heptamers at the injection site depot.53 The size 
of the heptamer and the strong self-association 
facilitate the prolonged and delayed absorption 
of liraglutide from subcutaneous tissue. After 
entering the bloodstream, the fatty acid chain 
allows reversible binding of liraglutide to 
serum albumin, providing partial stability and 
resistance to DPP-4 catabolism.16 The above 
pharmacokinetic mechanisms account for the 
protracted mechanism of action of liraglutide 
and are consistent with once-daily dosing.
Evidence from preclinical studies in animal 
models has shown that treatment with liraglutide 
improves aspects of beta-cell proliferation and 
function, ameliorates glycemic control, reduces 
bodyweight and positively affects cardiac 
function. After 6 weeks of treatment with 
liraglutide, Zucker diabetic fatty rats exhibited 
significantly increased beta-cell mass and a 
trend towards enhanced beta-cell proliferation 
compared with controls.54 In recent in-vitro 
studies using human pancreatic islet cells, 
liraglutide promoted beta-cell proliferation, 
inhibited interleukin-1 beta-induced apoptosis 
and increased pancreatic islet mass and size.55
Alongside its positive effects on beta-cells, 
liraglutide was also found to exert a significant 
effect on appetite suppression, food intake and 
weight in animal models of diabetes and obesity.56
Liraglutide treatment has also proven to have 
positive effects on the cardiovascular system, 
increasing survival, reducing cardiac rupture 
risk, and improving cardiac function in a mouse 
model of experimental myocardial infarction.32
In support of results from preclinical studies, 
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with T2DM have shown that liraglutide can 
increase beta-cell function in the fasting state 
by 30% compared with placebo, as assessed 
by homeostasis model assessment for beta-cell 
function.57 The same trial showed that maximum 
beta-cell secretory capacity was significantly 
higher after treatment with liraglutide, compared 
with placebo, and that proinsulin/insulin ratio 
(a measure of beta-cell stress and dysfunction) 
was reduced by 40% to 50%, a further indication 
of improved beta-cell function. Furthermore, 
liraglutide increases insulin secretion in a strictly 
glucose-dependent manner, and improves both 
first-phase and second-phase insulin responses 
in subjects with T2DM, as assessed by means 
of a hyperglycemic clamp.57 With liraglutide, 
glycemic control is improved by dose-dependent 
lowering of both fasting and postprandial plasma 
glucose concentrations in diabetic patients, and 
this effect lasts for the entire 24-hour dosing 
period. While establishing tight glycemic 
control remains the central objective of diabetes 
treatment, tackling comorbid obesity is also of 
major importance, as obesity per se constitutes 
a significant risk factor for a wide range of 
cardiometabolic complications in diabetic 
patients. Contrary to many existing antidiabetic 
agents, which are frequently associated with 
undesirable weight gain, liraglutide has shown 
positive effects on the mechanisms underlying 
weight loss. More specifically, it delays the 
rate of gastric emptying, reduces ad libitum 
energy intake and exerts a modest suppression 
of hunger sensation, as indicated by diverse 
appetite rating endpoints.58
Encouraging preclinical and phase 2 clinical 
trial results led to the comprehensive program 
LEAD (Liraglutide Effect and Action in Diabetes), 
involving over 4456 enrolled patients from more 
than 600 sites in 40 countries, of whom over 
2739 individuals with T2DM were treated with 
liraglutide for up to 52 weeks. The program 





(weeks) Compared randomized regimens
LEAD-1 1041 26 Liraglutide+SU versus SU+TZD
LEAD-2 1091 26 Liraglutide+MET versus MET+SU
LEAD-3 746 52 Liraglutide monotherapy versus SU monotherapy
LEAD-4 533 26 Liraglutide+MET+ TZD versus MET+TZD
LEAD-5 581 26 Liraglutide+MET+SU versus glargine+MET+SU
LEAD-6 464 26 Liraglutide+MET and/or SU versus exenatide+ MET and/or SU
Lira-DPP-4i 665 26 Liraglutide+MET versus sitagliptin+MET
LEAD=Liraglutide Effect and Action in Diabetes ; Lira-DPP-4i=liraglutide-sitagliptin trial; MET=metformin; 
SU=sulfonylurea (glimepiride); TZD=thiazolidinedione (rosiglitazone).
In LEAD-1, liraglutide added to glimepiride was well tolerated and provided improved glycemic control and favorable 
weight profile, compared with adding rosiglitazone to glimepiride. In LEAD-2, liraglutide induced similar glycemic control, 
reduced bodyweight, and lowered the incidence of hypoglycemia, compared with glimepiride, when they were both added 
to pre-existing metformin treatment. In LEAD-3, liraglutide proved to be both safe and effective as initial pharmacological 
therapy for T2DM, and led to greater reductions in HbA1c, weight, hypoglycemia, and blood pressure than glimepiride 
monotherapy. In LEAD-4, liraglutide combined with metformin and rosiglitazone proved to be a well tolerated combination 
therapy for T2DM, and provided significant improvement in glycemic control. In LEAD-5, the strategy of adding liraglutide 
to combined treatment with glimepiride and metformin proved to be non-inferior to adding basal insulin glargine in terms 
of HbA1c reduction. In LEAD-6 head-to-head study of liraglutide once daily versus exenatide twice daily (as add-on to 
metformin and/or sulfonylurea therapy), mean HbA1c reduction was significantly greater with liraglutide treatment than 
with exenatide.59-65112 Diabetes Ther (2011)  2(2):101-121.
consisted of LEAD-1 to LEAD-6 (all including 
active comparator treatments), while the 
liraglutide-sitagliptin trial (Lira-DPP-4i) was a 
26-week randomized head-to-head comparison 
of liraglutide against DPP-4 inhibitor sitagliptin, 
when added on to pre-existing metformin 
treatment. Table 3 provides a synopsis of LEAD 
studies. The LEAD program and Lira-DPP-4i 
trial have demonstrated that liraglutide, both 
as monotherapy and in combination with a 
variety of antidiabetic drugs, is associated with 
substantial improvements in HbA1c, fasting 
and postprandial glucose levels, and improved 
beta-cell function, as measured by HOMA-B 
and proinsulin/insulin ratio.59-65 Meta-analyses 
of the LEAD trials have consistently shown 
that liraglutide is associated with greater HbA1c
reductions in patients with higher baseline 
HbA1c, and that the extent of HbA1c reduction 
with liraglutide is independent of concomitant 
weight loss experienced.66 It is noteworthy that 
liraglutide lowered HbA1c by up to 2.5% from 
baseline in patients with poor initial glycemic 
control (HbA1c >10%), which was significantly 
greater than active comparators. A meta-analysis 
of LEAD trials has also shown that significant 
reductions in systolic blood pressure (by up to 
2.6 mmHg from baseline) could be achieved 
within 2 weeks of liraglutide treatment, before 
any major weight loss could be observed, 
and these reductions were independent of 
concomitant treatment with antihypertensive 
medication and sustained for up to 26 weeks.66
Across all LEAD trials, liraglutide led to 
significant weight loss in T2DM patients, and 
primarily reduction of body fat. The majority 
of body fat lost proved to be visceral abdominal 
fat, while weight loss effect of liraglutide was 
becoming more prominent with increasing 
baseline body mass index.59-65 Regarding the 
total cardiovascular burden of diabetic patients 
treated with liraglutide, total cholesterol, 
low-density lipoprotein cholesterol, free fatty 
acids, triglycerides, brain-derived natriuretic 
peptide, and high-sensitivity C-reactive 
protein levels were all significantly decreased 
from baseline after 26-week treatment with 
liraglutide.66 These data suggest that beyond 
its established effects on glycemic control, 
weight, and systolic blood pressure, liraglutide 
might contribute to clinically relevant 
cardiovascular risk reduction via additional, 
as yet undetermined, physiological effects. 
Concerning the impact of antidiabetic treatment 
on patient-reported health-related quality of 
life, overall patient satisfaction was better with 
liraglutide versus comparators such as exenatide, 
sitagliptin, and glimepiride.59,64,67 Across the 
entire spectrum of LEAD phase 3 clinical trials, 
liraglutide was generally well tolerated, with 
mild to moderate transient nausea being the 
most commonly reported treatment-related 
adverse event. Furthermore, a pooled analysis of 
four LEAD trials demonstrated that only 8.6% 
of patients developed anti-liraglutide antibodies, 
and this immunologic response has never been 
associated with reduced efficacy of liraglutide.68
CLINICAL EFFICACY OF ONCE-
WEEKLY (LONG-ACTING) 
GLUCAGON-LIKE PEPTIDE 1 
ANALOGS
Albiglutide
Albiglutide (formerly known as albugon) 
is a long-acting GLP-1R agonist, developed 
by GlaxoSmithKline through the genetic 
fusion of two repeats of human GLP-1(7-36) 
molecules to recombinant human albumin.69
The GLP-1 dimer was used in order to enhance 
the interaction of the GLP-1 monomer with its 
receptor in the presence of albumin. A single 
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hydrolysis site (conversion of alanine to glycine 
at position 8) renders the molecule resistant to 
DPP-4 inactivation.70 The structure of albiglutide 
provides an extended half-life of 5-8 days, 
which may allow weekly or less frequent dosing 
regimens. The randomized, double-blind, 
controlled phase 2 clinical study by Rosenstock 
et al. aimed to evaluate efficacy, safety, and 
tolerability of incremental doses of albiglutide, 
administered subcutaneously with three dosing 
schedules (4, 15, or 30 mg weekly; 15, 30, 
or 50 mg biweekly; 50 or 100 mg monthly) 
in 356 patients with T2DM, inadequately 
controlled with diet and exercise or metformin 
monotherapy.71 Significant dose-dependent 
reductions in HbA1c (from –0.79 to –0.87%) 
and weight loss (–1.1 to –1.7 kg) were observed 
within all albiglutide treatment groups.71 The 
incidence of gastrointestinal adverse events 
(nausea, vomiting, and flatulence) in subjects 
receiving albiglutide 30 mg weekly was less 
than that observed for the highest biweekly 
and monthly doses of albiglutide.71 Albiglutide 
is relatively impermeant to the central nervous 
system, which may have implications for a 
better gastrointestinal tolerability profile when 
compared with exenatide.72 Several clinical trials 
examining the use of albiglutide as combination 
therapy in T2DM are currently ongoing and 
their results are awaited with anticipation.
Taspoglutide
Taspoglutide (R1583/BIM51077) is a novel 
human GLP-1 analog developed by Ipsen SA, 
which is now licensed and has been moved into 
phase 3 clinical trials by Hoffmann-La Roche.73
Taspoglutide is similar in structure to native 
human GLP-1(7-36) amide, except for two amino 
acid substitutions (93% sequence homology 
with native GLP-1) in positions 8 and 35 with 
aminoisobutyric acid, which render the molecule 
resistant to degradation by DPP-4.73 Short-term 
efficacy of taspoglutide was clinically evaluated 
by Kapitza et al. in patients with T2DM.74
Three cohorts with 12 diabetic patients in each 
were given single subcutaneous injections of 
taspoglutide (1, 8, or 30 mg) and four diabetic 
patients were randomized to placebo. The highest 
doses of 8 and 30 mg resulted in significant 
improvements in glycemic parameters such as 
fasting blood glucose, 24-hour blood glucose 
profile, and 5-hour postprandial blood glucose 
levels.74 With the 30 mg dose of taspoglutide, 
the maximum effect on metabolic parameters 
was observed 14 days after injection, but was 
still evident for up to 28 days after injection. 
In the double-blind, placebo-controlled study 
by Nauck et al. in T2DM patients inadequately 
controlled with metformin alone, taspoglutide at 
doses 5/10/20 mg weekly or 10/20 mg biweekly 
improved significantly fasting and postprandial 
glucose control and elicited substantial weight 
loss, when combined with metformin.75 The 
magnitude of improvement in glycemic control 
observed with taspoglutide after 8 weeks 
(–1.1% decrease in HbA1c from a baseline of 
7.9%) compared favorably with that seen with 
other GLP-1R agonists, such as exenatide and 
liraglutide. Phase 3 clinical trials are currently 
in progress.
Exenatide Long-Acting Release Formulation
Exenatide has been developed by Amylin 
Pharmaceuticals in a sustained/long-acting 
release formulation (LAR) planned for once-
weekly subcutaneous administration. This LAR 
is based on a common biodegradable medical 
polymer, used in bioabsorbable sutures and other 
extended-release pharmaceuticals containing 3% 
exenatide peptide.76,77 In patients with T2DM who 
are inadequately controlled with metformin and/
or diet, 0.8 and 2.0 mg of exenatide once weekly 114 Diabetes Ther (2011)  2(2):101-121.
for 15 weeks resulted in HbA1c reductions of 1.4% 
and 1.7% compared with an increase of 0.4% in 
the placebo group.78 The 2 mg group experienced 
a weight loss of 3.8 kg versus no weight change 
in the other groups. Drucker et al. compared the 
effect of 10 μg exenatide twice daily and 2 mg 
exenatide LAR once weekly in 295 patients with 
T2DM, who were suboptimally controlled on 
lifestyle intervention and/or oral antidiabetic 
treatment.79 In this study, exenatide LAR once 
weekly was superior to exenatide twice daily 
in terms of glycemic parameters. Interestingly, 
glucagon levels decreased significantly more 
with exenatide once weekly versus exenatide 
twice daily.79 Additionally, significantly greater 
reductions in total and low-density lipoprotein 
cholesterol levels were observed with the once-
weekly exenatide formulation, compared with 
twice-daily exenatide.79 Both treatments elicited 
equally significant improvements in fasting 
triglyceride levels, systolic and diastolic blood 
pressure. Anti-exenatide antibodies were formed 
in 67% of exenatide LAR-treated patients78 and 
were comparatively higher among exenatide LAR-
treated patients as opposed to exenatide twice-
daily-treated patients.79 It cannot be excluded 
that high titers of such antibodies may be 
associated with diminished therapeutic efficacy.
SAFETY ISSUES AND OVERALL 
CONCERNS ASSOCIATED WITH 
INCRETIN-BASED THERAPY
In early preclinical studies in rodents, long-
term exposure to the GLP-1R agonist liraglutide 
was associated with upregulation of calcitonin 
gene expression and thyroid C-cell hyperplasia, 
adenomas, or even carcinomas at the highest 
doses.80 Although in-vitro rodent experiments 
have suggested involvement of GLP-1R in C-cell 
neoplasia,81 it is important to acknowledge the 
species-specific differences between rodents 
and humans in GLP-1R expression and activity 
at the level of thyroid tissue, which need to be 
seriously considered, while trying to interpret 
the preclinical observations. In rodents, there 
is high expression and activity of GLP-1R on 
thyroid C-cells, while humans have low thyroid 
expression of GLP-1R, and GLP-1R agonists 
do not appear to stimulate calcitonin release 
to a clinically relevant degree.81 In the clinical 
setting, LEAD trials with up to 2 years duration 
and over 2700 enrolled patients suggested no 
direct carcinogenic or growth-promoting effects 
of liraglutide, as no patient developed medullary 
thyroid carcinoma.59-65
Another theoretical risk associated with 
incretin-based therapy is the risk of acute or 
chronic pancreatitis, which has been raised 
during postmarketing surveillance both for 
GLP-1 analogs and DPP-4 inhibitors. A small 
number of cases with pancreatitis have been 
reported in patients treated with exenatide, 
liraglutide, sitagliptin, and saxagliptin,82 without, 
however, being able to establish the causal or 
incidental nature of this relationship, as T2DM 
patients are predisposed to develop pancreatitis 
at a higher rate than the general population 
regardless of type of antidiabetic treatment due to 
concomitant obesity and hypertriglyceridemia.83
Up-to-date clinical and experimental datasets 
linking GLP-1R agonists and DPP-4 inhibitors to 
pancreatitis remain incomplete.
Further concerns related to treatment with 
GLP-1R agonists include the potential fear of 
self-injections and the commonly observed 
difficulty in tolerating the gastrointestinal side-
effects, in particular nausea, during the first 
weeks of treatment. Despite the ongoing effort 
to minimize the number of injections to once-
weekly or once-monthly regimens, the concept 
of injectable treatments causes considerable 
anxiety and distress to a subgroup of patients, 
who strongly insist on being treated with oral Diabetes Ther (2011)  2(2):101-121. 115
agents, even at the cost of suboptimal glycemic 
control. As far as nausea is concerned, although 
it is mild in severity and transient in duration 
in the majority of cases, it can be perceived as a 
greatly unpleasant and worrisome adverse event 
by some patients, who are prone to abandon 
treatment shortly after nausea of any severity 
is experienced. Beyond safety and tolerability 
issues, the pharmacoeconomic parameters of 
incretin-based treatment merit also serious 
consideration, as the high cost of GLP-1 analogs 
and DPP-4 inhibitors can become prohibitive 
for some healthcare systems. It is important 
that large-scale cost-effectiveness analyses are 
performed in the future in order to conclude 
whether the high cost of these agents can be 
counterbalanced by the cost savings associated 
with prevention of complications or reducing 
the frequency of blood glucose monitoring.
Unresolved Issues and Future Perspectives
The critical question that remains unanswered 
in the field of incretin research is whether 
incretin-based therapies are able to exhibit a 
long-term favorable impact on beta-cell mass 
and function, suggesting the potential to alter 
the natural course of T2DM. Given the current 
lack of noninvasive imaging methods that 
enable direct in-vivo quantitative assessment 
of beta-cell mass in humans, a reasonable 
option to test the validity of this intriguing 
theory would be to perform long-term clinical 
trials in order to evaluate the durability of 
glycemic control that can be achieved with 
GLP-1R agonists or DPP-4 inhibitors. If long-
term glycemic control is established with these 
agents, it could be assumed that they exert 
chronic positive effects on beta-cell health, as 
the major factor underlying worsened glycemic 
control under treatment is the progressive loss 
of islet mass.
There are also a number of issues related 
to incretin-based therapy that warrant further 
investigation. For example, the preclinical 
findings suggesting cardioprotective actions of 
theoretically inactive metabolite GLP-1(9-36) 
through GLP-1R-independent mechanisms,28
needs further confirmation. The validation 
of these findings would indicate that 
DPP-4 inhibitors might be deprived of such 
cardioprotective potential by blocking the 
conversion of the active GLP-1 metabolite to its 
inactive form. Another interesting theory that 
merits further research is that once-daily GLP-1R 
agonists, such as liraglutide, are more effective 
in controlling fasting rather than postprandial 
hyperglycemia, while twice-daily GLP-1R 
agonists, such as exenatide, and DPP-4 inhibitors 
are more effective in controlling postprandial 
rather than fasting hyperglycemia.84 Another 
interesting area of research is delineating the 
exact mechanisms by which GLP-1 analogs 
suppress glucagon secretion from pancreatic 
alpha-cells, as it remains controversial whether 
GLP-1Rs are expressed on the surface of human 
alpha-cells. It has been shown that GLP-1Rs 
could not be detected in purified rat alpha-
cells, while their direct exposure to GLP-1 did 
not alter glucagon secretion.85,86 As a result, an 
indirect action, mediated by the stimulatory 
effect of GLP-1 on neighboring beta-cells or 
delta-cells and resulting in intra-islet paracrine 
inhibition of glucagon release, might also be 
a biologically plausible explanation. Further 
research in this field may provide insight into 
how inappropriate glucagon secretion could be 
therapeutically controlled in T2DM.
Future directions for research related to 
incretin-based therapy include clinical trials with 
combined regimens of basal or prandial insulin 
with GLP-1R agonists or DPP-4 inhibitors, 
novel indications based on the emerging 
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of GLP-1R agonists, and a comprehensive 
pharmacoeconomic evaluation of the cost-
effectiveness profile of incretin-based therapies 
in order to answer the question of whether their 
high cost can be offset by their overall clinical 
benefit. In terms of safety issues, monitoring of 
pancreatic function and serum calcitonin levels 
in patients chronically treated with incretin-
based therapies in the context of ongoing, long-
term, prospective, controlled clinical trials is 
considered to be a prudent approach.
CONCLUSION
The development of incretin-based therapies 
promises to dramatically alter the current 
therapeutic landscape of T2DM. The glucose-
lowering properties of GLP-1 analogs are now 
well established. In addition, continuing research 
suggests that GLP-1-based therapy has potential 
benefits far more wide-ranging than its isolated 
effects on glucose metabolism and bodyweight. 
In order for a glucose-lowering agent to improve 
cardiovascular outcomes, which is the ultimate 
goal for T2DM management, it may need to 
impact multiple key drivers of atherosclerotic 
complications, such as dyslipidemia, 
hypertension, subclinical inflammation, 
endothelial dysfunction, and increased 
thrombogenicity. It becomes increasingly evident 
that GPL-1 mimetics are able to counteract some 
of the above critical abnormalities.
The optimal therapy for T2DM patients 
should be able to secure all of the following 
clinical benefits: adequate glycemic control 
with minimal risk of hypoglycemia, substantial 
improvement of the beta-cell function, clinically 
meaningful weight loss, effective control of 
diabetes-related cardiovascular risk factors such 
as hypertension and dyslipidemia, and a simple 
and flexible treatment regimen. It is true that the 
majority of currently available oral antidiabetic 
agents cannot sufficiently address the critical 
therapeutic issues mentioned above. Based on 
the accumulating and encouraging clinical 
evidence reviewed herein, GLP-1R agonists may 
be able to provide some reliable solutions to 
the intractable problem of suboptimal T2DM 
management and have the potential to fulfill 
the currently unmet therapy needs.
However, whether the positive 
cardiometabolic effects of GLP-1R agonists can 
also be translated into better clinical outcomes 
for diabetic patients in terms of long-term 
cardiovascular morbidity and mortality is 
currently unknown, and remains to be further 
elucidated within the context of prospective, 
well-designed, large-scale clinical trials.
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